It is reported that Sorafenib decreased constitutive STAT3 phosphorylation (Tyr705) as well as Mcl-1 and Bcl-xL expression in a dose-dependent manner to enhance TRAIL-mediated apoptosis in pancreatic cancer cell lines. This evidence concerns the gene STAT3 and familial pancreatic carcinoma.